Cowen reaffirmed their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a report published on Thursday, AnalystRatings.com reports. They currently have a $80.00 price objective on the biopharmaceutical company’s stock.
A number of other research analysts have also recently weighed in on ESPR. Stifel Nicolaus reiterated a buy rating on shares of Esperion Therapeutics in a research note on Thursday, June 13th. Credit Suisse Group set a €50.00 ($58.14) target price on shares of Fresenius SE & Co KGaA and gave the company a neutral rating in a research note on Monday, May 6th. Northland Securities set a $65.00 target price on shares of Esperion Therapeutics and gave the company a buy rating in a research note on Friday, June 14th. BidaskClub upgraded shares of Westport Fuel Systems from a hold rating to a buy rating in a research note on Friday, July 12th. Finally, Citigroup set a $73.00 target price on shares of Esperion Therapeutics and gave the company a buy rating in a research note on Tuesday, May 28th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of Buy and a consensus price target of $74.00.
Esperion Therapeutics stock opened at $43.10 on Thursday. Esperion Therapeutics has a fifty-two week low of $36.06 and a fifty-two week high of $60.99. The stock’s 50-day moving average price is $48.00.
In other Esperion Therapeutics news, CEO Timothy M. Mayleben purchased 5,000 shares of the company’s stock in a transaction that occurred on Friday, June 28th. The shares were bought at an average cost of $46.00 per share, for a total transaction of $230,000.00. Following the purchase, the chief executive officer now owns 66,163 shares of the company’s stock, valued at approximately $3,043,498. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 7.70% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. Advisor Group Inc. lifted its stake in shares of Esperion Therapeutics by 44.4% during the 4th quarter. Advisor Group Inc. now owns 947 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 291 shares in the last quarter. Parallel Advisors LLC purchased a new stake in shares of Esperion Therapeutics during the 1st quarter valued at approximately $80,000. Marshall Wace North America L.P. purchased a new stake in shares of Esperion Therapeutics during the 1st quarter valued at approximately $164,000. Xact Kapitalforvaltning AB purchased a new stake in shares of Esperion Therapeutics during the 2nd quarter valued at approximately $203,000. Finally, Paloma Partners Management Co purchased a new stake in shares of Esperion Therapeutics during the 4th quarter valued at approximately $207,000.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Featured Article: How Do Mutual Funds Work?
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.